Results 171 to 180 of about 18,081 (213)

Correction: Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression. [PDF]

J Biol Chem
Wang D, Yang X, Chen Y, Gong K, Yu M, Gao Y, Wu X, Hu H, Liao C, Han J, Duan Y.   +10 more
europepmc   +1 more source

The proprotein convertase FURIN is a novel aneurysm predisposition gene impairing TGF-β signalling. [PDF]

Cardiovasc Res
He Z, IJpma AS, Vreeken D, Heijsman D, Rosier K, Verhagen HJM, de Bruin JL, Brüggenwirth HT, Roos-Hesselink JW, Bekkers JA, Huylebroeck DFE, van Beusekom HMM, Creemers JWM, Majoor-Krakauer D.   +13 more
europepmc   +1 more source

Association between statin discontinuation after proprotein convertase subtilisin/kexin type 9 inhibitor initiation and subsequent atherosclerotic cardiovascular disease events. [PDF]

J Manag Care Spec Pharm
Peasah SK, Lee T, Do D, Huang Y, Inneh A, Patel U, Aiyer AN, Good CB.   +7 more
europepmc   +1 more source

Statins Versus Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Primary Cardiovascular Prevention in High-Risk Patients: A Systematic Review. [PDF]

Cureus
Khan S, Asif A, Omer O, Gondal MZD, Tallal H, Abbas T.   +5 more
europepmc   +1 more source

Successful use of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Hypertriglyceridemia-induced Acute Pancreatitis: A Case Report. [PDF]

Curr Cardiol Rev
Qi R, Liu H, Li X, Chen M.
europepmc   +1 more source

Advancing Research on Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Scientometric Analysis. [PDF]

Malays J Med Sci
Matin A, Chaudhry GE, Azra MN, Gazali M, Yeong YS, Tengku Muhammad TS.   +5 more
europepmc   +1 more source

Proprotein convertase subtilisin/kexin type 9 as a drug target for abdominal aortic aneurysm. [PDF]

Curr Opin Lipidol
Golledge J, Lu HS, Shah S.
europepmc   +1 more source

Nonalcoholic Fatty Liver Disease Risk and Proprotein Convertase Subtilisin Kexin 9 in Familial Hypercholesterolemia Under Statin Treatment. [PDF]

Nutrients
Hamasaki M, Sakane N, Kotani K.
europepmc   +1 more source

Retraction Note: Potential use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and prevention method in viral infection. [PDF]

Microb Cell Fact
Muzammil K, Hooshiar MH, Varmazyar S, Omar TM, Karim MM, Aadi S, Kalavi S, Yasamineh S.   +7 more
europepmc   +1 more source